TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04956549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Successful Aging
Description: The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
Study: NCT05627583

Intervention type: OTHER
Intervention: Rehabilitation
Description: Hospitalized patients with AN under treatment for rehabilitation
Study: NCT05561296

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femtosecond laser assisted cataract surgery with astigmatism management
Description: The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femtosecond laser assisted cataract surgery with astigmatism management
Description: The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
Study: NCT05451056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
Study: NCT05849610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered by oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by subcutaneous (SC) injection.
Study: NCT04771000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Endothelin receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06175585

Intervention type: OTHER
Intervention: traditional nursing
Description: Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
Study: NCT05074355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
Study: NCT05464381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allo-APZ2-OTS
Description: Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05537480

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring device
Description: Continuous glucose monitoring device will be worn by participants during several periods.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring device
Description: Continuous glucose monitoring device will be worn by participants during several periods.
Study: NCT06023719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISC Care
Description: Medical device to prevent disc herniation recurrence
Study: NCT05673590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Injection
Description: Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel Injection
Description: Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs.
Study: NCT00733928

Intervention type: DEVICE
Group type: OTHER
Intervention: PFC Sigma knee with all-poly tibial component
Description: Orthopaedic implant for total knee replacement with an all-polyethylene tibial component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma knee with metal backed tibia
Description: Orthopaedic implant for total knee replacement with a metal-backed tibial component
Study: NCT04907474

Intervention type: DRUG
Group type: OTHER
Intervention: tropicamide-phenylephrine fixed combination ophthalmic solution
Description: Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis

Intervention type: DRUG
Group type: OTHER
Intervention: tropicamide-phenylephrine fixed combination ophthalmic solution
Description: Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis
Study: NCT06286293

Intervention type: OTHER
Intervention: Neuropsychological assessment, driving simulator task
Description: Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
Study: NCT06117761

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercises combined with cognitive training
Description: An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercises
Description: An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
Study: NCT06263296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management Education
Description: Smartphone assisted self management education incorporated with the concept of motivational interviewing
Study: NCT05155800

Intervention type: DEVICE
Intervention: SDx3
Description: The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.

Intervention type: DEVICE
Intervention: SDx3
Description: The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.

Intervention type: DEVICE
Intervention: SDx3
Description: The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
Study: NCT06048900

Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound guided optic nerve sheath diameter measurement
Description: First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
Study: NCT06180369

Intervention type: OTHER
Group type: OTHER
Intervention: BeutiSealant (Shofu, Kyoto, Japonya)
Description: Fissur Sealent application
Study: NCT05707299

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intradermal acupuncture
Description: Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20\*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture
Description: Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20\*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level.
Study: NCT05559203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: danceSing Care
Description: The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
Study: NCT04739449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching, Cleaning, Communication, Collaboration
Description: 1. Coaching staff~2. Cleaning protocols, standardized~3. Communication with staff and leadership~4. Collaboration with local expertise
Study: NCT05960851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05074186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurological thrombectomy device is an investigational device.
Description: Revascularization device is an investigational device.
Study: NCT06286293

Intervention type: OTHER
Intervention: Neuropsychological assessment, driving simulator task
Description: Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.

Intervention type: OTHER
Intervention: Neuropsychological assessment, driving simulator task
Description: Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.

Intervention type: OTHER
Intervention: Neuropsychological assessment, driving simulator task
Description: Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
Study: NCT05053659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS).
Study: NCT05454761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Lifestyle Medicine Program
Description: Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Lifestyle Medicine Program
Description: Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.
Study: NCT05791760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT) for complex PTSD
Description: The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.
Study: NCT05810207

Intervention type: PROCEDURE
Intervention: Colorectal resection
Description: Patients undergoing a colorectal resection with the construction of a primary anastomosis
Study: NCT04143984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy
Description: Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Carbon-ion radiotherapy
Description: Accelerated carbon-ion beam with pencil beam scanning technique.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon-ion radiotherapy
Description: Accelerated carbon-ion beam with pencil beam scanning technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: An anti-PD-1 antibody.
Study: NCT05097950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of 1 gr paracetamol I.V
Description: Administration of 1 gr paracetamol I.V

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of 1 gr paracetamol I.V
Description: Administration of 1 gr paracetamol I.V
Study: NCT04798768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mCRM Therapy System
Description: Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
Study: NCT05694650

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
Study: NCT04910776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Description: Sterile lyophilized powder intravenous (IV) infusion
Study: NCT06082037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Tablet, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Depends on pharmaceutical presentation, Oral
Study: NCT05567211

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Free use of the virtual platform.
Description: Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.
Description: Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
Study: NCT06082037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Depends on pharmaceutical presentation, Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral